Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026Unaudited cash ...

Key market opportunities in CD137-targeted therapies include the upcoming commercial launch by 2030, robust clinical trial activity with over 90 therapies, and promising combination therapies.

FOSHAN, GUANGDONG, CHINA, January 14, 2026 /EINPresswire.com/ -- Foshan AoChuanShun New Material Industrial Co., Ltd.

A "gene silencer" (technically known as small interfering RNA, or siRNA), locally delivered by nanoparticles embedded in an ...

As demand for Men Balance Pro grows in 2026, so does the risk of counterfeit products, unauthorized resellers, and purchases that do not qualify for refunds. One pattern appears consistently across ...

In 2026, The Brain Song reviews have sparked serious discussion across neuroscience and cognitive-health circles. At the center of the debate is a simple but disruptive question: can targeted sound ...

This latest addition to CML Micro’s extensive portfolio enables manufacturers to develop next-generation radio devices with ...

Berger has participated in meetings (lectures, advisory boards, consultations) sponsored and compensated by pharmaceutical ...